- Home
- PHAR vs PBT Comparison
PHAR vs PBT Comparison
Compare PHAR & PBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- PBT
- Stock Information
- Founded
- PHAR 1988
- PBT 1980
- Country
- PHAR Netherlands
- PBT United States
- Employees
- PHAR N/A
- PBT N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- PBT Oil & Gas Production
- Sector
- PHAR Health Care
- PBT Energy
- Exchange
- PHAR Nasdaq
- PBT Nasdaq
- Market Cap
- PHAR 951.7M
- PBT 838.5M
- IPO Year
- PHAR N/A
- PBT N/A
- Fundamental
- Price
- PHAR $13.18
- PBT $17.86
- Analyst Decision
- PHAR Strong Buy
- PBT
- Analyst Count
- PHAR 3
- PBT 0
- Target Price
- PHAR $30.00
- PBT N/A
- AVG Volume (30 Days)
- PHAR 9.7K
- PBT 98.4K
- Earning Date
- PHAR 11-06-2025
- PBT 01-01-0001
- Dividend Yield
- PHAR N/A
- PBT 1.84%
- EPS Growth
- PHAR N/A
- PBT N/A
- EPS
- PHAR N/A
- PBT 0.35
- Revenue
- PHAR $339,836,000.00
- PBT $18,413,820.00
- Revenue This Year
- PHAR $17.70
- PBT N/A
- Revenue Next Year
- PHAR $12.25
- PBT N/A
- P/E Ratio
- PHAR N/A
- PBT $50.51
- Revenue Growth
- PHAR 22.44
- PBT N/A
- 52 Week Low
- PHAR $7.31
- PBT $8.01
- 52 Week High
- PHAR $17.08
- PBT $19.52
- Technical
- Relative Strength Index (RSI)
- PHAR 43.85
- PBT 49.69
- Support Level
- PHAR $13.03
- PBT $17.89
- Resistance Level
- PHAR $13.43
- PBT $18.77
- Average True Range (ATR)
- PHAR 0.49
- PBT 0.64
- MACD
- PHAR -0.10
- PBT 0.03
- Stochastic Oscillator
- PHAR 23.47
- PBT 54.04
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.